SCHEMBL1994788

SCHEMBL1994788

O=C(O)N1CCc2[nH]cnc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.38
HTR2C P28335 1/20 0.35
KDM4E B2RXH2 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
AKT1 P31749 2/20 0.33
ADRA1A P35348 1/20 0.33
AOC3 Q16853 1/20 0.32
POLB P06746 2/20 0.32
ENPP2 Q13822 1/20 0.32
BRD4 O60885 2/20 0.32
CREBBP Q92793 2/20 0.32
EP300 Q09472 1/20 0.32
SCN9A Q15858 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
MAPK1 P28482 1/20 0.31
HTR3A P46098 2/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13505458 0.87 NAMPT (0.48) NAMPTHTR2CKDM4EHRH4HRH3
SCHEMBL12662820 0.85 BAZ2B (0.43) NAMPTENPP2BRD4CREBBPEP300
SCHEMBL30141445 0.84 NAMPT (0.38) NAMPTHTR2CKDM4EHRH4HRH3
SCHEMBL22915890 0.82 KDM4E (0.47) NAMPTHTR2CKDM4EKCNH2
SCHEMBL15492450 0.81 CREBBP (0.47) NAMPTHTR2CKDM4EHRH4HRH3
SCHEMBL11515494 0.81 BAZ2B (0.43) NAMPTHTR2CHRH4HRH3AKT1
SCHEMBL4154205 0.81 ENPP2 (0.36) NAMPTHTR2CKDM4EHRH4HRH3
SCHEMBL22916009 0.79 NPC1 (0.47) KDM4EENPP2EP300
SCHEMBL11518308 0.79 TMPRSS2 (0.42) NAMPTHTR2CAKT1ADRA2A
SCHEMBL6423555 0.78 HRH4 (0.39) NAMPTHTR2CKDM4EHRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738044-B2 Therapeutic compound and use in therapy PROXIMAGEN, LLC (US) 2020-08-11 US claimed
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US claimed
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
CN-115677729-A AAK1 inhibitors 武汉人福创新药物研发中心有限公司 2023-02-03 CN disclosed
WO-2022178215-A1 AMINO AMIDE TETRAHYDRO IMIDAZO PYRIDINES AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-08-25 WO disclosed
EP-3558990-B1 TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS INCYTE CORP (US) 2022-08-10 EP disclosed
WO-2022089511-A1 BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-05-05 WO disclosed
CN-113939295-A Pyridazinones and methods of use thereof 金翅雀生物公司 2022-01-14 CN disclosed
WO-2021136354-A1 BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2021-07-08 WO disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 EP disclosed
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases NOVARTIS AG (CH) 2008-11-13 US disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
EP-1689391-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
EP-1622897-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Novartis AG (CH) 2006-02-08 EP disclosed
WO-2005021519-A2 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES NOVARTIS AG (CH) 2005-03-10 WO disclosed
WO-2004096797-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2004-11-11 WO disclosed
WO-2002038153-A1 NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES BIOVITRUM AB (SE) 2002-05-16 WO disclosed
EP-1173438-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2002-01-23 EP disclosed
WO-2000063208-A1 SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN NAMPT 612/4885HTR2C 489/4885KDM4E 3899/4885
US-10738044-B2 Therapeutic compound and use in therapy PIGO, GOT2, OAT NAMPT 699/4885HTR2C 789/4885KDM4E 518/4885
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase PIK3CA, PIP4K2C, PIP4K2B NAMPT 2574/4885HTR2C 3003/4885KDM4E 1826/4885
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE CD274, PDCD1LG2, PDCD1 NAMPT 3435/4885HTR2C 2665/4885KDM4E 3669/4885
US-20080280871-A1 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases PI4KA, IP6K3, PHOSPHO1 NAMPT 2080/4885HTR2C 3838/4885KDM4E 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.